desmoid tumor
Jump to navigation
Jump to search
Etiology
- history of trauma in 25%
- breast implant-associated desmoid tumors
- retroperitoneal neoplasms may be associated with surgery for familial polyposis coli or Gardner syndrome
Epidemiology
- rare, most common in premenopausal women
Pathology
- fibrous neoplasms originating from the muscular aponeuroses
- often infiltrative
- usually well-differentiated
- firm overgrowths of fibrous tissue
- locally invasive & aggressive, but not metastatic[2]
- tendency for recurrence
Genetics
Clinical manifestations
- they most commonly develop in the anterior abdominal wall & shoulder girdle
- rarely appear on the foot
- tumors are firm, smooth, & mobile
- often adhere to surrounding structures
- overlying skin is usually unaffected
- intra-abdominal desmoid tumors remain asymptomatic until growth & infiltration cause visceral compression resulting in pain & functional impairment
Laboratory
- biopsy with immunostaining for
- vimentin
- alpha smooth muscle actin
- muscle actin
- desmin
- APC gene mutation
Radiology
- imaging useful for diagnosis & follow-up
Management
- surgery with negative surgical margins
- positive margins associated with high risk of recurrence
- radiation therapy
- nirogacestat (Ogsiveo) FDA approved to treat progressive, unresectable, recurrent, or refractory desmoid tumors[2]
More general terms
Additional terms
References
- ↑ Schwartz RA and James WD
- ↑ 2.0 2.1 2.2 Otto MA FDA Approves Nirogacestat for Desmoid Tumors. Medscape. November 27, 2023 https://www.medscape.com/viewarticle/998820